The aim of our study was to analyze the value of prostate gland volume measurement by transrectal ultrasonography (TRUS) in prediction of severity of lower urinary tract symptoms (LUTS). Material and methods: One hundred and one patients undergoing TRUS guided core needle prostate biopsy for the investigation of prostate cancer were prospectively evaluated. All patients had filled in the international prostate symptom score (IPSS) scala, has been tested for PSA and prostate volume measurement was done by TRUS prior to biopsy. According to their biopsy results, patients were divided into two groups: negative and positive for malignancy. Results: There was a significant but low correlation of 0.37 between IPSS and prostate volume measurement by TRUS (p=0.001). Serum free prostate specific antigen (fPSA), total PSA (tPSA), ratio of fPSA to tPSA and PSA density did not show a statistically significant correlation with IPSS (p>0.05). No statistically significant difference in IPSS between the benign and malignant groups (p=0.681) was found. In the benign group, mean IPSS was 14.59 ± 8.73, range: 0-35 while in the malignant group, mean IPSS was 15.33 ± 9.22, range: 3-28. Conclusions: Prostate volume measurement by TRUS is a poor predictor for the determination of the severity of LUTS therefore IPSS should be primarily considered for the determination of the severity of LUTS. Also, according to this study conducted with patients who were at their first set of prostate biopsy, IPSS cannot be used as a predictor of malignancy. PSA values were not related to IPSS.
Introduction
Prostatic enlargement resulting in benign prostatic hyperplasia (BPH) is a chronic, progressive disease which is common in male population mostly after the sixth decade [1] . BPH presents with lower urinary tract symptoms (LUTS) related to voiding (slow stream, splitting or spraying, intermittency, hesitancy, straining and terminal dribble), storage (increased daytime frequency, nocturia, urgency and urinary incontinence), and post-micturition (feeling of incomplete emptying, post-micturition dribble) consequently decreasing the quality of life [2] .
The initial diagnostic challenge in patients presenting with LUTS is to establish that the symptoms are due to BPH. Then the secondary aim is to determine the severity of BPH [3] . In the evaluation of BPH determination of the symptom score, medical history, digital rectal examination, urinalysis, serum prostate specific antigen (PSA) measurement are suggested for men over 50 years old. Urinary cytologies, transrectal ultrasonography (TRUS) measurement of the prostate, uroflowmetry, postvoid residual urine volume analysis, pressure-flow urodynamics, and filling cystometry are additional examinations which can be performed with a specific purpose such as to confirm the diagnosis, to determine the severity of BPH, or to choose treatment [4, 5] .
The severity of LUTS can be evaluated by the American Urological Association Symptom Score (AUASS) or the International Prostate Symptom Score (IPSS). AUASS is a scala which consists of seven questions involving LUTS related to voiding and storage, IPSS incorporates one additional question about the affect of LUTS on the quality of life [6] [7] [8] . Enlargement of prostate volume is associated with aggravation of LUTS, acute urinary retention and increased need for BPH surgery [6] . Prostatic volume assessment is therefore considered to be useful to determine treatment options and outcomes [7, 9, 10] . Measurement of prostate volume using ultrasonography (US) comprises different approaches, mainly transrectal and sometimes transabdominal. Transrectal route is reported to be the most accurate method [11, 12] .
In this research we aimed to analyze the value of prostate gland volume measurement by TRUS in prediction of the severity of LUTS due to the fact that there are only a few studies analyzing this correlation in the English literature.
Material and methods
Following the approval of the local Ethics Committee of our institution, from August 2013 to January 2014, 113 consecutive patients referred to our Radiology Department by the Urology Department for TRUS guided core needle prostate biopsy for the exclusion of malignancy were considered for this study.
Study group
Among the 113 men above the age of 50 referred for TRUS guided core needle prostate biopsy to exclude malignancy, 5 patients were excluded due to inappropriate International Normalized Ratio (INR) value (>1.4) and 7 patients due to the history of previously known prostate malignancy and/or previous radiation therapy. None of the patients had other possible causes of LUTS such as metabolic disorders (diabetes mellitus, nephrogenic type diabetes insipidus), neurologic disorders (multiple sclerosis, cerebrovascular events, lumbosacral disc diseases) or concomitant use of pharmacological agents (diuretics, alpha-agonists, anticholinergics) according to the prior detailed medical history. The remaining 101 patients constituted the study cohort. All patients were informed about the study and gave their written consent Serum analysis Serum samples were obtained a week before prostate biopsy. Free PSA (fPSA) and total PSA (tPSA) values were measured by chemiluminescence immunoassay kit in the biochemistry department of our institution. The reference range of free PSA was accepted as 0-3.3 ng/mL and total PSA was accepted as 0-3.9 ng/mL. Ratio of fPSA to tPSA and PSA density which is the ratio of total PSA to prostate volume was later calculated for each patient.
IPSS
Prior to the biopsy all patients included in the study filled in the IPSS scale (seven questions related to LUTS questioning the severity of incomplete emptying, fre-quency, intermittency, urgency, weak stream, straining and nicturia). The answers were assigned points from 0 to 5 increasing with the severity of the symptoms. The total score therefore ranged between 0 to 35. There was also one question for the evaluation of the quality of life which was not included in the calculation of the total score. Categorization of LUTS symptoms were interpreted as mild (symptom score ≤7), moderate (symptom score range between 8 to 19) and severe (symptom score range between 20 to 35).
TRUS and biopsy TRUS evaluation and volume measurement of the prostate gland followed by TRUS guided core biopsy were performed in all patients by two radiologists with 12 and 10 years of sonography experience in consensus using Logiq S6, GE Healthcare, Little Chalfont, United Kingdom. Prostate volume was measured using the prolate ellipse formula (height x width x length x π/6) [13] . Six core biopsy materials were obtained from each lobe covering all segments, making a total of 12 biopsies for each patient. An automatic core biopsy device (Bio-Pince® Full-Core Biopsy Instruments; Surgical Specialties Co. (Angiotech), Vancouver, Canada) with a 18 G (1.2 mm) x 20 cm needle, adjusted to 13 or 23 mm stroke length, according to the depth of the prostate gland, was used for the biopsy procedure.
Pathology Biopsy specimens were fixated and transferred in 10% formaldehyde solution. Tissue samples were embedded in paraffin and routine hematoxylin-eosin staining was applied to section samples. If necessary, immunohistochemical staining was applied. According to the pathological evaluation of the TRUS guided biopsy samples, patients were divided into two groups: negative and positive for malignancy.
Statistical analysis
Statistical analysis were performed by statistics software; SPSS 16 (Chicago, USA). Independent Sample T-Test was used to analyze the presence of a difference in age, height and body-mass index (BMI) between the groups negative and positive for malignancy. To analyze the presence of a difference in weight, prostate volume and IPSS between the groups negative and positive for malignancy Mann-Whitney U test was used. Spearman correlation coefficient analysis was done for the correlation between age, weight, height, BMI, prostate volume and IPSS as well as between age, weight, height, BMI and prostate volume. P values less than 0.05 were considered to be statistically significant.
Results
The patient characteristics of our study group are presented in table I. In the whole group there was a low positive correlation between age with IPSS (0.24, p=0.05 and 0.23 respectively, p=0.05) and a low negative correlation between height and IPSS (0.20, p=0.05). Weight and BMI did not show a statistically significant correlation with IPSS (p>0.05). There was a statistically significant but low correlation of 0.37 between IPSS and prostate volume (p=0.001) (fig 1) . There was a low positive correlation between BMI and weight with prostate volume (0.34 and 0.27 respectively, p=0.05). Age and height did not show a statistically significant correlation with prostate volume (p>0.05).
After histopathological examination 15 patients were found positive for malignancy. The comparison between the 2 groups (negative and positive for malignancy) is detailed in table II.
Discussions
According to the results of this study there was a statistically significant correlation between prostate volume measurement by TRUS and IPSS. This means that the patients with larger prostate volume have higher IPSS, hence experience more severe LUTS. But the low Spearman correlation (0.37) between prostate volume and IPSS showed that the reliability of prostate volume measurement by TRUS seems to be questionable for the determination of the severity of LUTS.
Sciarra et al [14] evaluated 400 men with LUTS and investigated the presence of difference in age, IPSS and prostate volume in 543 patients with and without benign prostatic hyperplasia. Authors reported that IPSS was weakly correlated with age and prostate volume. They concluded that the weak correlation was a result of their study sample which was selected among the patients from the urology clinic [14] . Eckhardt et al [15] also carried out a study which investigated the difference in IPSS, prostate volume and urodynamic findings in male volunteers with and without LUTS and in patients with LUTS suggestive of BPH. Their results indicated that volunteers without LUTS had smaller prostate volumes, less residual volume, lower symptom scores, a lower urethral resistance factor, a higher maximal free flow rate and a higher effective capacity than volunteers with LUTS. These variables were closely similar in volunteers with LUTS to those of the patients with LUTS except prostate volume being smaller in the former group [15] . In another prospective study including 120 patients Udeh et al analyzed the correlation between pre-treatment IPSS in BPH patients and prostate volume measured by transabdominal US. Authors did not find a significant correlation between IPSS and prostate volume [16] . Aktas et al investigated the effect of prostate volume on voiding function and IPSS score deterioration after TRUS guided prostate biopsy. Authors concluded that patients with prostate volume greater than 38.8 mL were more likely to have decreased IPSS scores following TRUS guided prostate biopsy [17] .
Concerning the relation between IPSS and prostate volume, our results were in accordance with the study of Sciarra et al but remotely coherent with the study of Aktas as we utilized TRUS in our study, which is considered to be more accurate for determining the prostate volume. Thus we believe that our results are more dependable regarding the correlation between IPSS and prostate volume.
Our study has some limitations. The study group was limited in number and included only patients with LUTS from the urology clinic. Further investigations with study cohorts including non-urological patient groups are required for analyzing the correlation between IPSS and prostate.
Conclusions
Prostate volume measurement by TRUS is a poor predictor for the determination of the severity of LUTS and IPSS should be primarily considered for the determination of the severity of LUTS. On the other hand according to this study conducted with patients who were at their first set of prostate biopsy, IPSS cannot be used as a predictor of malignancy. PSA values are not related to IPSS.
